EC
NTLA icon

EcoR1 Capital’s Intellia Therapeutics NTLA Stock Holding History

EcoR1 Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-200,858
Closed -$3.42M – 37
2016
Q3 		$3.42M Sell
200,858
-109,837
-35% -$2.13M 1.05% 25
2016
Q2 		$6.63M Buy
+310,695
New +$8.27M 2.62% 15

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

EcoR1 Capital's NTLA Position: Q4 2016 in Review

EcoR1 Capital sold out of Intellia Therapeutics (NTLA) in Q4 2016, closing a stake of 200,858 shares — an estimated $3.42M sold.

EcoR1 Capital first reported a position in NTLA in Q2 2016 and held it in 2 quarters. The position peaked at $6.63M in Q2 2016. 70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • EcoR1 Capital reported no remaining Intellia Therapeutics position as of Q4 2016 after selling out during the quarter.
  • EcoR1 Capital sold 200,858 Intellia Therapeutics shares in Q4 2016, an estimated $3.42M.
  • EcoR1 Capital first reported a position in Intellia Therapeutics in Q2 2016 and held it in 2 quarters.
  • EcoR1 Capital's Intellia Therapeutics position peaked at $6.63M in Q2 2016.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on EcoR1 Capital's 13F filing for Q4 2016, filed 14 Feb 2017.